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Abstract
Background—The adipocyte fatty acid–binding protein (FABP) aP2 is expressed by adipocytes
and macrophages and modulates insulin resistance, glucose and lipid metabolism, and
atherosclerosis. Insulin sensitivity is improved in obese but not in lean aP2-deficient mice. A
second fatty acid–binding protein, mal1, also is expressed in adipocytes and macrophages, and
mal1 deficiency produces similar effects on insulin resistance. We tested the hypothesis that
combined aP2 and mal1 deficiency would produce synergistic effects on metabolism and reduce
atherosclerosis in apolipoprotein E–deficient (apoE−/−) mice.
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Methods and Results—Male and female apoE−/− mice null for both aP2 and mal1 (3KO) and
apoE−/− controls were fed a low-fat chow diet for 16 or 56 weeks. Lean 3KO mice had
significantly lower serum cholesterol and triglycerides as well as improved insulin and glucose
tolerance as compared with controls. Analysis of atherosclerotic lesions in the 3KO mice showed
dramatic reductions in both early (20 weeks) and late-stage (60 weeks) atherosclerosis. Strikingly,
survival in the 3KO mice was improved by 67% as compared with apoE−/− controls when
challenged with the Western diet for 1 year.
Conclusions—Combined aP2 and mal1 deficiency improved glucose and lipid metabolism,
reduced atherosclerosis, and improved survival in apoE−/− mice, making these proteins important
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therapeutic targets for the prevention of the cardiovascular consequences of the metabolic
syndrome.
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The metabolic syndrome is the clustering of insulin resistance, hyperinsulinemia,
hypertension, dyslipidemia, and impaired fibrinolysis observed primarily in patients with
visceral obesity.1 The metabolic syndrome is recognized as a major risk factor for the
development of type 2 diabetes mellitus and atherosclerosis.2 In murine models, the
adipocyte fatty acid–binding protein aP2 modulates features of the metabolic syndrome,
including insulin resistance, triglyceride metabolism, and atherosclerosis.3–5

NIH-PA Author Manuscript

Cytoplasmic fatty acid–binding proteins (FABPs) are a family of cytoplasmic proteins that
bind fatty acid ligands with high affinity. Their functions include shuttling free fatty acids
(FFAs) to various intracellular compartments, regulating cellular lipid metabolism and
expression of inflammatory cytokines, and modulating gene expression.6 aP2 is highly
expressed in adipocytes and macrophages.7–9 Its expression is transcriptionally controlled
during adipocyte development and regulated by PPARγ agonists, insulin, and fatty
acids.10,11 In the macrophage, aP2 expression is stimulated on exposure to phorbol esters,
oxidized low-density lipoproteins, and PPARγ ligands.4,9,12 Both adipocytes and
macrophages express a second FABP, mal1 (also known as keratinocyte lipid-binding
protein or skin FABP), which is also found in the epidermis, mammary tissue, and testis.4,13
Studies in aP2-deficient mice have shown that aP2 plays a significant role in many aspects
of the metabolic syndrome. aP2 deficiency protects mice with dietary or genetic obesity
from the development of insulin resistance, hyperglycemia, and hypertriglyceridemia.3,14
Recently, mal1 deficiency also was shown to partially improve glucose homeostasis and
insulin sensitivity in obese mice15; however, lean (ie, normal body weight for age) aP2−/−
and mal1−/− mice on a standard chow diet show no significant alterations in glucose and
cholesterol levels as compared with wild-type mice.3,15
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Our previous work demonstrated that aP2 deficiency protects lean apolipoprotein E (apoE)–
deficient (apoE−/−) mice from both early and advanced atherosclerosis without significant
effects on systemic glucose and lipid metabolism.4,5 Bone marrow transplantation studies
showed that macrophage aP2 expression promotes foam cell formation and atherosclerosis.4
Macrophage aP2 deficiency reduces the cellular accumulation of cholesterol esters and
inhibits the expression of inflammatory cytokines.4 aP2 deficiency leads to upregulation of
mal1 expression in the adipocyte but not in the macrophage.4 Because aP2 and mal1 are
coexpressed in adipocytes and macrophages and mal1 is able to compensate for aP2
deficiency, we hypothesized that a combined deficiency of aP2 and mal1 would have
synergistic effects on glucose metabolism and atherosclerosis. In the present study, we show
that combined aP2 and mal1 deficiency improves glucose and lipid metabolism, reduces
atherosclerosis, and, as a result, dramatically improves survival in the apoE−/− mouse model.
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Methods
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Animal Procedures
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aP2-deficient and mal1-deficient mice were generated by using homologous recombination
in embryonic stem cells, as described.3,15 We generated aP2−/− mal1−/− apoE−/− (3KO,
experimental group) mice by first crossing aP2−/− and mal1−/− mice (both backcrossed >10
generations into C57BL/6J background) to generate aP2−/− mal1−/− mice. The aP2−/−
mal1−/− mice were then crossed with apoE−/− animals (all on C57BL/6J background) and
the F1 aP2+/− mal1+/− apoE+/− progeny were intercrossed with each other. Age- and sexmatched aP2+/+mal1+/+apoE−/− mice (also on C57BL/6J background) were used as controls.
Mice were fed a standard chow diet with 4.5% fat (PMI feeds) ad libitum beginning at 4
weeks of age for 16 weeks. For mouse survival studies, male 3KO and apoE−/− mice were
individually caged and maintained on a high-fat atherogenic Western diet (Harlan Teklad,
diet No. TD88137: 21% fat, 0.15% cholesterol, 0% cholate) ad libitum beginning at 4 weeks
of age for 52 weeks. These animals were not subjected to any experimentation and only
survival was recorded for 1 year. At the end of 1 year, the experiment was stopped because
of animal facility guidelines, although no deaths occurred in the 3KO group. Animal care
and experimental procedures were performed with approval from the animal care
committees of Vanderbilt and Harvard Universities.
Serum Measurements
Mice were fasted overnight (12 h) and blood samples were collected by retro-orbital venous
plexus puncture under isoflurane (AErrane, Baxter Pharmaceutical Products) anesthesia.
Serum cholesterol and triglycerides were determined with reagent kits (Raichem and SigmaAldrich) as described.16 Fasting serum glucose was determined by colorimetric assay
(Schiapparelli BioSystems). Plasma FFAs were measured by colorimetric assay (Wako Pure
Chemical Industries), and plasma adiponectin levels were measured by radio-immunoassay
kit (Linco Research). Lipoprotein analysis by fast protein liquid chromatography (FPLC)
was performed on fasting serum samples, as previously described.17 The mean peak area of
apolipoprotein B (apoB)–containing lipoproteins was calculated as the sum of fractions 14
to 25 (very-low-density lipoprotein and intermediate-density lipoprotein/low-density
lipoprotein peaks) for each animal in milligrams per deciliter.

NIH-PA Author Manuscript

Metabolic Measurements
Insulin tolerance tests (ITT, 0.5 IU/kg body weight) and glucose tolerance tests (GTT, 1.8
g/kg body weight) were performed on conscious mice after a 6-h fast.18 Mesenteric fat from
euthanized animals was quantified by determining the total mesenteric fat wet weight in
grams for each animal. To measure the portal vein FFA in the fasting and fed states, we
anesthetized mice by intraperitoneal administration of 10 mg/kg xylazine (Phoenix
Pharmaceuticals) and 100 mg/kg ketamine (Fort Dodge Animal Health), surgically exposed
the portal vein, and collected blood samples with a syringe and 28-gauge needle.
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Assessment of Arteriosclerosis and Immunohistochemistry
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Perfusion fixation, preparation of aortas, and quantification of atherosclerotic lesions in the
en face aorta were performed as previously described.19 Lesions in the proximal aorta from
serial 10-μm-thick cryosections were stained with Oil Red O, counterstained with
hematoxylin, and quantified as described.20,21 For the detection of mal1 protein in proximal
aorta lesions, 5-μm serial cryosections from 15-week-old chow-fed aP2−/− apoE−/− or aP2−/−
mal1−/− apoE−/− mice were incubated with rabbit antiserum against human mal1 (gift of Dr
Rex Parker, Bristol-Myers Squibb). Sections were then incubated with secondary
biotinylated anti-rabbit antibodies, visualized with Fast Red TR/Napthol AS-NX substrate
(Sigma-Aldrich), and counterstained with hematoxylin.17 Macrophages were detected with
rat monoclonal antibody against mouse macrophage marker (MOMA-2, Accurate Chemical
and Scientific).17
Statistical Analysis
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The mean values for biochemical data from each group were compared by Student t test.
The atherosclerosis data were analyzed with a nonparametric Mann-Whitney test. The
survival curve data were analyzed by log-rank test. All statistical tests with P<0.05 were
considered significant.

Results
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To examine the role of combined aP2 and mal1 deficiency on metabolism and
atherosclerosis, we placed 4-week-old male (n=15) and female (n=13) 3KO mice and male
and female apoE−/− controls (n=15 and n=12, respectively) on a chow diet for 16 weeks.
Fasting levels of serum cholesterol, triglycerides, and glucose at 20 weeks are summarized
in Table 1. Mean cholesterol levels were 18% lower in male 3KO mice (P=0.048) and 29%
lower in female 3KO mice (P=0.0001) as compared with controls. Similarly, mean fasting
triglycerides were 32% lower in male 3KO mice (P=0.009) and 42% lower in female 3KO
mice (P=0.0006) as compared with controls. Analysis of the lipoprotein distribution by size
exclusion chromatography demonstrated significant quantitative differences in the peak
height of the apoB-containing particles between groups (Figure 1). Male 3KO mice (Figure
1A) showed a 13% reduction in the mean peak of the apoB-containing lipoproteins
(321.4±40.1 versus 368.5±18.7, mean±SD mg/dL, P=0.026) as compared with apoE−/−
mice. Female 3KO mice (Figure 1B) had a 26% reduction in mean peak of apoB-containing
lipoproteins (244.6±44.2 versus 330.9±76.2, mean±SD mg/dL, P=0.02) as compared with
apoE−/− mice. No significant differences in mean plasma FFA levels were found after a 12-h
fast as compared with controls for each sex (Table 1).
Serum glucose levels were virtually identical between the male 3KO mice and controls
(Table 1); however, a significant 48% reduction was observed in fasting serum glucose
levels of female 3KO mice as compared with controls (40±12 versus 77±35 mg/dL, mean
±SD, P=0.0017). Both male and female 3KO groups showed better glucose tolerance than
apoE−/− controls (Figure 2C and 2D), which was particularly striking in the female 3KO
mice. In accordance with the improved glucose tolerance, both male and female 3KO mice
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demonstrated greater insulin sensitivity on ITT as compared with controls (Figure 2A and
2B).
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Mean body weight at 16 weeks of age was ≈10% lower in the male 3KO mice as compared
with controls (Table 2); however, no significant difference in mean body weight was
observed between female 3KO mice and apoE−/− controls. We also measured plasma
adiponectin levels in all 4 groups after a 12-h fast but found no significant differences
between groups for either sex (Table 2). We measured mesenteric fat weight and portal vein
FFA levels in a subset of male 3KO and apoE−/− mice, as shown in Table 2. No significant
difference (P=0.17) was found in mesenteric fat weight in the 3KO mice (n=4) as compared
with controls (n=4). No significant difference was detected in portal vein FFA levels in the
fed state between groups, but a significant increase in fasting portal vein FFA levels was
noted in the 3KO mice as compared with controls (P=0.04).
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To assess the effects of combined aP2 and mal1 deficiency on atherosclerosis, we
euthanized the mice at 20 weeks for lesion analysis of the proximal and en face aortas. We
previously showed that aP2 protein is expressed by macrophages within the atherosclerotic
lesions of the proximal aorta in apoE−/− mice.4 mal1 protein also is abundantly expressed
within atherosclerotic lesions and colocalizes with the macrophage marker MOMA-2
(Figure 3). Male 3KO mice showed a 53% reduction in mean lesion area in the proximal
aorta (58 631±6638 versus 125 165±17 331 μm2/ section, mean±SEM, P=0.003) and a
similar 45% reduction in mean lesion area of the en face aorta (0.172±0.030 versus
0.311±0.031%, mean±SEM, P=0.006) as compared with control apoE−/− mice (Figure 4A).
Female 3KO mice showed a 37% reduction in proximal aorta lesion area (127 784±14 522
versus 203 284±23 728 μm2/section, mean±SEM, P=0.01) and a 37% lower mean lesion
area of the en face aorta (0.259±0.025 versus 0.413±0.063%, mean±SEM, P=0.024). To
determine whether the reduction in atherosclerosis would be persistent even in the setting of
advanced atherosclerosis, we fed 6 male 3KO mice and 5 male apoE−/− mice a regular chow
diet and euthanized them at 60 weeks of age. Dramatic reductions in mean serum cholesterol
(291±38 versus 424±55 mg/dL, mean±SD, P=0.002) and triglycerides (61±18 versus
135±21 mg/dL, mean±SD, P=0.0003) were persistent at 60 weeks of age in the 3KO mice as
compared with controls. As shown in Figure 4C, a 26% reduction in atherosclerosis of the
proximal aorta was observed in 60-week-old male 3KO mice as compared with controls
(375 351±22 279 versus 507 218±35 164 μm2/section, mean±SEM, P=0.017). We found an
impressive 78% reduction of the en face aorta lesion area (4.11±0.99 versus 18.54±2.57%,
mean±SEM, P=0.004) in 60-week-old 3KO mice as compared with controls (Figure 4D and
4E).
Because of the improvements in lipid and carbohydrate metabolism and atherosclerosis, we
hypothesized that combined FABP deficiency would have an impact on longevity in 3KO
mice. To evaluate this finding, we placed male 3KO (n=13) and apoE−/− (n=12) mice on a
Western diet beginning at 4 weeks of age for 1 year. Survival was dramatically improved at
1 year of age (100% versus 33%, P=0.0004) in 3KO mice as compared with controls (Figure
5).
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Discussion
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Numerous studies have demonstrated the importance of cellular fatty acid metabolism in the
pathogenesis of insulin resistance. Mice with deficiency of the type B scavenger receptor
CD36, which is also a fatty acid transporter, show lower plasma glucose and insulin levels
on a chow diet but higher serum cholesterol and triglyceride levels than wild-type mice.22
Mice with deficiency of aP2 or mal1 alone demonstrate no significant alterations in insulin
sensitivity when they are lean on a chow diet3,15; however, these mice are partially protected
from the insulin resistance and hyperglycemia caused by genetic or diet-induced
obesity.3,14,15 In the present study, we found a remarkable improvement in insulin
sensitivity in lean 3KO mice on a chow diet, indicating a synergistic effect of combined aP2
and mal1 deficiency on glucose metabolism. Adipose tissue from aP2−/− mice have a major
upregulation of mal1 expression, which partially compensates for the effects of aP2
deficiency in the adipocyte.3,23 Evidence for this result is demonstrated by the
overexpression of mal1 in adipose tissue using a transgenic mouse model, which results in a
phenotype of impaired glucose tolerance.15 In 3KO mice, the elimination of mal1 eliminates
this compensation for aP2 deficiency, which likely contributes to the dramatic enhancement
in insulin sensitivity observed in lean animals.
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Lean and obese aP2-deficient mice show reductions in serum triglycerides but no changes in
serum cholesterol levels as compared with wild-type mice.3,14 However, we found that
combined FABP deficiency of aP2 and mal1 results in significant improvements in total
serum cholesterol and triglycerides despite the presence of severe dyslipidemia resulting
from apoE deficiency. In contrast, lean aP2−/− apoE−/− mice demonstrate no significant
differences in cholesterol or triglyceride levels as compared with apoE−/− mice on a chow or
high-fat Western diet.4,5 Lean chow-fed mal1-deficient mice show modest reductions in
serum cholesterol and triglycerides as compared with wild-type mice, but this difference is
abolished in the setting of obesity-induced dyslipidemia.15 In addition, mal1−/− apoE−/−
mice display no reductions in serum lipids as compared with apoE−/− mice on a chow diet
(Jeffrey Boord, MD, unpublished data, 2003). Thus, combined aP2 and mal1 deficiency
appears to have additive effects on lipid metabolism in vivo.
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Chronic elevations in FFA and visceral obesity have been implicated as contributors to
insulin resistance and dyslipidemia in the metabolic syndrome.24 We did find a small
reduction in the body weight of the male 3KO mice as compared with controls, but we did
not find a significant difference in visceral adipose tissue content as measured by mesenteric
fat weight. We found no difference in portal vein FFA levels in the fed state, and we noted a
significant increase in portal vein FFA in the fasting state in 3KO mice. Thus, the
enhancement in insulin and glucose sensitivity in 3KO mice does not appear to be the result
of reduced mesenteric fat content or lower systemic and portal vein FFA levels. aP2deficient adipose tissue shows striking reductions in the secretion of several inflammatory
cytokines, including a dramatic reduction in tumor necrosis factor-α.3 It is likely that
interference with this and other inflammatory responses plays at least a partial role in the
phenotype of FABP-deficient mice.3,15 Adiponectin, a cytokine produced by adipocytes and
suppressed in obesity and type 2 diabetes mellitus, improves insulin sensitivity and reduces
serum triglycerides in mice in vivo.25,26 We considered whether increased adiponectin
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secretion could account for the improvements in glucose and lipid metabolism in 3KO mice,
but we found no differences in plasma adiponectin levels between groups.
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apoE−/− mice that receive aP2−/− apoE−/− bone marrow are protected from atherosclerosis
without changes in lipid or glucose metabolism.4 Thus, macrophage aP2 can promote foam
cell formation independent of any effects on insulin resistance. In the present study,
combined aP2 and mal1 deficiency had remarkable effects on both insulin sensitivity and
lipid metabolism in lean animals. Thus, the observed metabolic changes likely contributed to
the protection from both early and advanced atherosclerosis. As a result of the
improvements in lipid metabolism that were observed in 3KO mice, it was not possible to
directly compare atherosclerotic lesion development with aP2−/− apoE−/− mice, which show
no significant improvements in lipids or insulin sensitivity on chow or Western diets.4,5
Because mal1 expression is upregulated in the adipocyte but not in the macrophage with aP2
deficiency, the potential exists for a differential impact of combined aP2 and mal1
deficiency in the adipocyte as compared with the macrophage.4 Future studies will address
the relative contributions of aP2 and mal1 expression in the macrophage and the adipocyte
to atherogenesis.

NIH-PA Author Manuscript

The most compelling finding of the present study was the improved survival in 3KO mice as
compared with apoE−/− mice on a high-fat diet. Other investigators have reported
spontaneous plaque rupture and intraplaque hemorrhage in older apoE−/− mice (>30 weeks
old) on both chow and high-fat diets.27,28 Williams et al29 reported that apoE−/− mice on a
high-fat diet showed an average time of sudden death at 29 weeks of high-fat feeding. The
primary causes of death could not be determined, but plaque rupture in the brachiocephalic
artery was noted frequently and some apoE−/− mice experienced myocardial infarctions.29
Johnson and Jackson27 found ruptured atherosclerotic plaques in the brachiocephalic artery
in 7 of 8 apoE−/− mice fed a high-fat diet that died suddenly. In our longevity study, the
primary cause of death was not determined by necropsy, but we believe cardiovascular
events resulting from plaque rupture would be the most likely cause of death in the apoE−/−
mice.
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It is possible that combined aP2 and mal1 deficiency contributes to enhanced plaque
stability and thus reduces vascular events that lead to sudden death. Other investigators have
shown that antiinflammatory therapies such as low-dose aspirin therapy and inhibition of the
CD40 signaling pathway30,31 in mouse models can lead to increases in atherosclerotic lesion
collagen content consistent with enhanced plaque stability. Preliminary studies in our
laboratory suggest that increased collagen deposition is found in 3KO mice as compared
with apoE−/− controls after 16 weeks on the Western diet (Jeffrey Boord, MD, unpublished
data, 2003). It is important to note that limitations exist in using murine models of plaque
stability and rupture. Significant differences in plaque remodeling and hemodynamics are
found in murine versus human arteries, and the low incidence of plaque rupture in the
proximal aorta in mice makes the study of spontaneous plaque rupture difficult.28,32 Further
study of plaque morphology in mice with combined aP2 and mal1 deficiency may provide
insight into the effects of lipid metabolism, insulin resistance, and inflammation on plaque
stability.
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In summary, combined aP2 and mal1 deficiency produces beneficial effects on glucose and
lipid metabolism in lean animals and reduces atherosclerosis in vivo. These benefits are
persistent even in advanced age, with combined aP2 and mal1 deficiency conferring a
significant survival benefit in the setting of apoE deficiency. The increased cardiovascular
risk related to the metabolic syndrome in humans results from the combined effects of
insulin resistance, hyperinsulinemia, dyslipidemia, and impaired fibrinolysis on the
vasculature.1 This action makes modulation of these FABPs attractive therapeutic targets for
treating or preventing cardiovascular consequences of the metabolic syndrome in humans.
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Figure 1.

Lipoprotein distribution by FPLC for 3KO and apoE−/− mice. Samples drawn from male (A)
and female (B) mice at 20 weeks of age after 12-h fast. Data are average distribution of total
cholesterol per fraction in mg/dL for each group. Fractions 14 to 18 contain VLDL; fractions
19 to 25, IDL/LDL; and fractions 26 to 31, HDL. Fractions 32 to 40 contain non–
lipoprotein-associated proteins.
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Figure 2.

GTT and ITT in 3KO and apoE−/− mice. ITT (0.5 U/kg, IP) shown for male (A) and female
(B) mice. GTT (1.8 g/kg, IP) shown for male (C) and female (D) mice. Each data point
represents mean glucose level (mg/dL)±SEM *P<0.05, as compared with control group.
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Figure 3.
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Immunocytochemical detection of macrophages and mal1 expression in atherosclerotic
lesions. Proximal aorta atherosclerotic lesions in aP2−/− apoE−/− and aP2−/− mal1−/− apoE−/−
mice stained with MOMA-2 to detect macrophages (A, B); mal1 expression (C, D) shown
with rabbit antiserum against human mal1 (magnification ×400).
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Figure 4.
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Atherosclerosis in proximal and en face aorta in 3KO and apoE−/− mice. Atherosclerosis in
20-week-old male and female mice in proximal aorta (A) and en face aorta (B).
Quantification of atherosclerosis for male 60-week-old mice in proximal aorta (C) and en
face aorta (D). Data shown as mean lesion area ±SEM for each group. *P<0.05. E,
representative pinned-out en face aorta preparations from male 60-week-old mice stained
with Sudan-IV, exemplifying dramatic reduction in lesion area in 3KO mice as compared
with apoE−/− controls (magnification ×20).
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Figure 5.

Survival curve for 3KO and apoE−/− mice on high-fat diet. Male 3KO and apoE−/− mice fed
high-fat Western diet at 1 month of age for 1 y. 3KO mice show significantly increased
survival at 12 months of age.
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Fasting Serum Biochemistry in aP2−/− mal1−/− apoE−/− (3KO) and apoE−/− Mice
Genotype (Sex)

Plasma FFA, mmol/L

Cholesterol, mg/dL

Triglycerides, mg/dL

Glucose, mg/dL

ApoE−/− (M) (n=15)

2.2±0.5

395±89

130±40

70±34

3KO (M) (n=15)

2.0±0.3

324±91*

88±24*

70±31

ApoE−/− (F) (n=12)

1.4±0.2

325±59

140±45

77±35

3KO (F) (n=13)

1.8±0.5

230±43*

81±28*

40±12*

Data are shown as mean±SD.
*

P<0.05 as compared with control.
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22±1.6
23±1.7

ApoE−/− (F)

3KO (F)

P<0.05 as compared with control.

*

Data are shown as mean±SD.

35.6±6.6

28±1.4*

3KO (M)

36.4±8.6

37.6±9.5

36.1±8.7

Plasma Adiponectin, μg/mL

30±2.0

Body Weight, g

ApoE−/− (M)

Genotype (Sex)

···

···

0.16±0.09

0.24±0.06

Mesenteric Fat Weight, g

···

···

1.15±0.31*

0.74±0.16

Portal Vein FFA, Fasting State, mmol/L

Indices of Adipocyte Function Between aP2−/− mal1−/− apoE−/− (3KO) and apoE−/− Mice

···

···

0.62±0.20

0.72±0.13

Portal Vein FFA, Fed State, mmol/L
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